Ribociclib
- Generic Name
- Ribociclib
- Brand Names
- Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O
- CAS Number
- 1211441-98-3
- Unique Ingredient Identifier
- TK8ERE8P56
- Background
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring tha...
- Indication
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05563220
- Locations
- 🇩🇪
Universitaetsklinikum Mannheim, Mannheim, Baden-Wuerttemberg, Germany
🇺🇸Dothan Hematology and Oncology, Dothan, Alabama, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT05508906
- Locations
- 🇺🇸
Advent Health Hematology and Oncology, Orlando, Florida, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Oana Danciu
- Target Recruit Count
- 200
- Registration Number
- NCT05467891
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona, Phoenix, Arizona, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Institut fuer Frauengesundheit
- Target Recruit Count
- 1000
- Registration Number
- NCT05452213
- Locations
- 🇩🇪
Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen, Bavaria, Germany
🇩🇪Department of Gynecology and Obstetrics, University Medicine Mainz, Mainz, Hesse, Germany
🇩🇪Klinikum St Marien Amberg, Amberg, Germany
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 231
- Registration Number
- NCT05429502
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸St Jude s Childrens Research Hospital, Memphis, Tennessee, United States
🇺🇸Cohen Children's Medical Center of New York, New Hyde Park, New York, United States
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Tvardi Therapeutics, Incorporated
- Target Recruit Count
- 6
- Registration Number
- NCT05384119
- Locations
- 🇺🇸
Holy Cross Health Fort Lauderdale - Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 346
- Registration Number
- NCT05358249
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸NYU School of Medicine, New York, New York, United States
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
- Conditions
- Metastatic HER2-Positive Breast CarcinomaPrognostic Stage IB Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT05319873
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
(VELA) Study of BLU-222 in Advanced Solid Tumors
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 366
- Registration Number
- NCT05252416
- Locations
- 🇺🇸
Hospital of the Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Roll-over Study to Allow Continued Access to Ribociclib
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT05161195
- Locations
- 🇺🇸
Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.